NeuroGenesis Bio Inc. is a clinical-stage cellular therapy company focused on developing novel and effective treatments for neurodegenerative diseases. The company has developed NG01 as a proprietary method to transform a unique subpopulation of marrow-derived cells into bio-factories for sustained delivery of regenerative and neuroprotective proteins. By promoting myelin and neuronal regeneration, the NG01 cellular therapy platform is optimized to treat neurodegenerative diseases such as progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). 

NG01 has been studied extensively in several clinical trials including a successful double blind, randomized, placebo-controlled Phase II study for progressive MS, and two long term (up to 4 years) Phase IIa trials for Progressive MS and ALS. To date, more than 160 progressive MS and ALS patients from around the world have been treated with this breakthrough therapeutic modality. 

Headquartered in Upstate NY, NeuroGenesis is steadily moving forward with a global, FDA-approved multi-site Phase IIb trial for secondary progressive multiple sclerosis, in partnership with major medical research centers in the United States and abroad.

For more information on the company, please visit: https://neurogenesis-cell.com/

NeuroGenesis Bio Inc.

Org chart

Teams

Offices